These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26717875)

  • 21. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.
    Aydin C; Sanlioglu AD; Karacay B; Ozbilim G; Dertsiz L; Ozbudak O; Akdis CA; Sanlioglu S
    Hum Gene Ther; 2007 Jan; 18(1):39-50. PubMed ID: 17187448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells.
    Kang S; Park SY; Lee HJ; Yoo YH
    Biochem Biophys Res Commun; 2010 Jun; 396(3):731-5. PubMed ID: 20451496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx.
    Moon DO; Kang CH; Kang SH; Choi YH; Hyun JW; Chang WY; Kang HK; Koh YS; Maeng YH; Kim YR; Kim GY
    Toxicol Appl Pharmacol; 2012 Feb; 259(1):87-95. PubMed ID: 22200406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Zhu J; Zhou Q; Tan S
    Cancer Lett; 2016 Dec; 383(2):154-160. PubMed ID: 27693456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
    Ruiz de Almodóvar C; Ruiz-Ruiz C; Rodríguez A; Ortiz-Ferrón G; Redondo JM; López-Rivas A
    J Biol Chem; 2004 Feb; 279(6):4093-101. PubMed ID: 14623878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
    van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
    Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
    Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
    Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
    J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
    Woo JK; Kang JH; Jang YS; Ro S; Cho JM; Kim HM; Lee SJ; Oh SH
    Oncol Rep; 2015 Apr; 33(4):1947-55. PubMed ID: 25672292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL.
    Jancekova B; Ondrouskova E; Knopfova L; Smarda J; Benes P
    Tumour Biol; 2016 Aug; 37(8):10685-96. PubMed ID: 26867770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
    Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
    PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors.
    You C; Zhang S; Sun Y; Zhang S; Tang G; Tang F; Liu X; Xiao Y; Zhang J; Gong Y; Xie C
    Int J Oncol; 2018 Nov; 53(5):2258-2268. PubMed ID: 30132512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
    Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
    Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.
    Peddaboina C; Jupiter D; Fletcher S; Yap JL; Rai A; Tobin RP; Jiang W; Rascoe P; Rogers MK; Smythe WR; Cao X
    BMC Cancer; 2012 Nov; 12():541. PubMed ID: 23171055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
    Reinhardt A; Liu H; Ma Y; Zhou Y; Zang C; Habbel JP; Possinger K; Eucker J
    Anticancer Res; 2018 May; 38(5):2669-2682. PubMed ID: 29715087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
    French R; Hayward O; Jones S; Yang W; Clarkson R
    Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.